Skip to main content
SpringerLink
Log in

Interferon Therapy of Neuroendocrine Tumours

  • Conference paper
Interferons

Abstract

Neuroendocrine gut and pancreatic tumours are considered to be rather rare neoplasms; however, due to increased awareness, improved diagnostic procedures and, not least, improved treatment, the number of cases has increased during the last two decades. The first case was described already in 1902 by Oberndorfer, who introduced the term carcinoid for a less malignant neoplasm. The incidence of patients with clinically significant carcinoid tumours is 0.5/100 000 and for endocrine pancreatic tumours 0.4/100 000. These are the two main groups of endocrine gastrointestinal tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Norheim I, Öberg K, Theodorsson-Norheim E et al (1987) Malignant carcinoid tumours: an analysis of 103 patients with regard to tumour localization, hormone production and survival. Ann Surg 206: 115–125.

    Article  PubMed  CAS  Google Scholar 

  2. Eriksson B, Arnberg H, Lindgren PG et al (1990) Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 228: 103–113

    Article  PubMed  CAS  Google Scholar 

  3. Wilander E, Lundqvist ML, Öberg K (1991) Gastrointestinal carcinoid tumors: progress in histochemistry and cytochemistry, vol 19, no. 2. Fischer, Stuttgart

    Google Scholar 

  4. Goodwin JD (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36: 560–569

    Article  Google Scholar 

  5. Moertel CG, Sauer WG, Dockerty MB, Baggentoss AH (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14: 901–912

    Article  PubMed  CAS  Google Scholar 

  6. Makridis C, Öberg K, Juhlin C et al (1990) Surgical treatment of midgut carcinoid tumors. World J Surg 14: 377

    Article  PubMed  CAS  Google Scholar 

  7. Thompson GB, van Heerden JA, Martin JK et al (1985) Carcinoid tumors of the gastrointestinal tract: Presentation, management and prognosis. Surgery 98: 1054

    PubMed  CAS  Google Scholar 

  8. Gaitan-Gaitan A, Riden WD, Rush RS (1975) Carcinoid tumor: cured by radiation. Radiat Oncol Biol Phys 1: 9

    Article  CAS  Google Scholar 

  9. Bauer P, van de Fierdt E, Stettmeier H, Langhammer HR, Pabst HW (1988) 125I-MIBG therapy of carcinoid tumor of intestinal origin. Eur J Nucl Med 14: 234

    Google Scholar 

  10. Stockman F, von Tomatowski HJ, Reimold WV, Schuster R, Creutzfeldt W (1984) Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with metastases. Z Gastroenterol 22: 652

    Google Scholar 

  11. Marlink RG, Lakich JJ, Robins JR, Clouse ME (1991) Hepatic arterial embolization of metastatic hormone secreting tumors. Cancer 65: 2227

    Article  Google Scholar 

  12. Venook A, Stagg R, Rye J, Gorden R, Ring E (1991) Chemoembolization of patients with liver metastases from carcinoid and islet cell tumors. Proc Amer Soc Clin Oncol (Abstract) 10: 386

    Google Scholar 

  13. Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5: 1503–1522

    Google Scholar 

  14. Hajarizadeh H, Ivancev K, Mueller CR et al (1992) Effective palliative treatment of metastatic carcinoid tumors with intraarterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 163: 479–483

    Article  PubMed  CAS  Google Scholar 

  15. Moertel CG (1983) Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1: 727–740

    PubMed  CAS  Google Scholar 

  16. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327–334

    PubMed  CAS  Google Scholar 

  17. Weiss RB (1982) Streptozocin: a review of its pharmacology, efficacy and toxicity. Cancer Treat Rep 66: 427–438

    PubMed  CAS  Google Scholar 

  18. Chernicoff D, Bukowski RM, Groppe CW et al (1979) Combination chemotherapy for islet carcinoma and metastatic carcinoid tumors with 5-FU and streptozotocin. Cancer Treat Rep 63: 795–796

    PubMed  CAS  Google Scholar 

  19. Eriksson B, Skogseid B, Lundqvist G (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65: 1883–1890

    Article  PubMed  CAS  Google Scholar 

  20. Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232

    Article  PubMed  CAS  Google Scholar 

  21. Reichlin D (1983) Somatostatin. N Engl J Med 309: 1495–1501, 1556–1563

    Article  PubMed  CAS  Google Scholar 

  22. Buscail LB, Esteve J-P, Saint-Laurent N et al (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580–1584

    Article  PubMed  CAS  Google Scholar 

  23. Kvols LK, Moertel CG, O’Connell MJ et al (1986) Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. N Engl J Med 315: 663–666

    Article  PubMed  CAS  Google Scholar 

  24. Öberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 4: 503–507

    Article  Google Scholar 

  25. Maton PN, Gardner JD, Jensen RT (1989) Use of long-acting somatostatin analog SMS 201–995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34: 28S–39S

    Article  PubMed  CAS  Google Scholar 

  26. Öberg K, Funa K, Alm G (1983) Effects of leucocyte interferon upon clinical symptoms and hormone levels in patients with mid-gut carcinoid tumours and the carcinoid syndrome. New Engl J Med 309: 129–133

    Article  PubMed  Google Scholar 

  27. Eriksson B, Öberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32: 203–208

    Article  PubMed  CAS  Google Scholar 

  28. Moertel CG, Rubin J, Kvols LK (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7 (7):865–868

    PubMed  CAS  Google Scholar 

  29. Norheim I, Öberg K, Alm G (1989) Treatment of malignant carcinoid tumors; a randomized controlled study of streptozocin plus 5-FU and human leucocyte interferon. Eur J Cane Clin Oncol 25: 1475–1479

    Article  Google Scholar 

  30. Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjö J, Dolva LO (1989) Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha-2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 24: 787–795

    Article  PubMed  CAS  Google Scholar 

  31. Bartsch HH, Stockmann F, Arnold R, Creutzfeldt W (1990) Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha - results from a phase II study. J Cancer Res Clin Oncol 116: 305

    Google Scholar 

  32. Välimäki M, Jarvinen H, Salmela P, Sane TA, Sjublom SM, Pelkonen R (1991) Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67: 547–549

    Article  PubMed  Google Scholar 

  33. Öberg K, Norheim I, Lind E et al (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Resp 70: 1297–1304

    Google Scholar 

  34. Öberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E (1989) Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b (Intron-A); development of neutralizing interferon antibodies and possible loss of antitumor activity. J Nat Cane Inst 81: 531–535

    Article  Google Scholar 

  35. Schober C, Schuppert F, Schmoll E, et al (1989) Interferon alpha-2b in patients with advanced carcinoids and apudoma. Blut 59: 331

    Google Scholar 

  36. Biesma B, Willemse PHB, Mulder NH et al (1992) Recombinant interferon alpha 2b in patients with metastatic apudomas; effect on tumours and tumour markers. Br J Cancer 66: 880–855

    Article  Google Scholar 

  37. Tiensuu Janson E, Ahlström H, Andersson T et al (1992) Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A:1647–1650

    Google Scholar 

  38. Tiensuu Janson E, Rönnblom L, Ahlström G, Alm G, Einhorn S, Öberg K (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3: 635–638

    Google Scholar 

  39. Tiensuu Janson E, Kauppinen H-L, Öberg K (1993) Combined alpha-and gamma-interferon therapy for malignant midgut carcinoid tumors. Acta Oncol 32: 231–233

    Article  Google Scholar 

  40. Rönnblom L, Alm GV, Öberg K (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178–183

    PubMed  Google Scholar 

  41. Baron S, Coppenhaver DH, Dianzani R, Fleischmann WR Jr, Hughes TK Jr, Klimpal GK, Niesei DW, Stanton GJ, Tyrm SK (eds) (1992) Interferon—principles and medical applications. The University of Texas Medical Branch, Texas

    Google Scholar 

  42. Funa K, Eriksson B, Wilander E, Öberg K (1991) Expression of chromogranin A and B mRNA in carcinoid tumors studied by in situ hybridization. Histochemistry 95–555–559

    Article  PubMed  CAS  Google Scholar 

  43. Grander D, Öberg K, Lundqvist M-L et al (1990) Interferon-induced enhancement of 2’–5’-oligoadenylate synthetase in mid-gut carcinoid tumors. Lancet 336: 337–340

    Article  PubMed  CAS  Google Scholar 

  44. Andersson T, Wilander E, Eriksson B, Lindgren PG, Öberg K (1990) Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 50: 3413–3415

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. K. Öberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Carlo Aul  & Wolfgang Schneider  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Öberg, K. (1997). Interferon Therapy of Neuroendocrine Tumours. In: Aul, C., Schneider, W. (eds) Interferons. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60411-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60411-9_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61051-9

  • Online ISBN: 978-3-642-60411-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation